[go: up one dir, main page]

EA200701771A1 - Низкомолекулярные ингибиторы mdm2 и их применение - Google Patents

Низкомолекулярные ингибиторы mdm2 и их применение

Info

Publication number
EA200701771A1
EA200701771A1 EA200701771A EA200701771A EA200701771A1 EA 200701771 A1 EA200701771 A1 EA 200701771A1 EA 200701771 A EA200701771 A EA 200701771A EA 200701771 A EA200701771 A EA 200701771A EA 200701771 A1 EA200701771 A1 EA 200701771A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mdm2
application
low molecular
molecular inhibitors
inhibitors
Prior art date
Application number
EA200701771A
Other languages
English (en)
Other versions
EA014445B1 (ru
Inventor
Шаомэн Ван
Кэ Дин
Ипинь Лу
Занета Николовска-Цолеска
Су Цю
Гопин Ван
Дунгуан Цинь
Санжеев Кумар
Original Assignee
Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган filed Critical Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган
Publication of EA200701771A1 publication Critical patent/EA200701771A1/ru
Publication of EA014445B1 publication Critical patent/EA014445B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к малым молекулам, которые функционируют как ингибиторы взаимодействия между р53 и MDM2. Изобретение также относится к применению этих соединений для ингибирования клеточного роста, включая клеточную гибель, индукцию остановки клеточного цикла и/или сенсибилизацию клеток к дополнительному агенту(ам).
EA200701771A 2005-02-22 2006-02-22 Низкомолекулярные ингибиторы mdm2 и их применения EA014445B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65513505P 2005-02-22 2005-02-22
PCT/US2006/006221 WO2006091646A2 (en) 2005-02-22 2006-02-22 Small molecule inhibitors of mdm2 and uses thereof

Publications (2)

Publication Number Publication Date
EA200701771A1 true EA200701771A1 (ru) 2008-06-30
EA014445B1 EA014445B1 (ru) 2010-12-30

Family

ID=36927977

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200701771A EA014445B1 (ru) 2005-02-22 2006-02-22 Низкомолекулярные ингибиторы mdm2 и их применения
EA201001255A EA019566B1 (ru) 2005-02-22 2006-02-22 Низкомолекулярные ингибиторы mdm2

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201001255A EA019566B1 (ru) 2005-02-22 2006-02-22 Низкомолекулярные ингибиторы mdm2

Country Status (11)

Country Link
EP (1) EP1856123B1 (ru)
JP (2) JP5248866B2 (ru)
KR (1) KR100944301B1 (ru)
CN (2) CN101160314B (ru)
AU (2) AU2006216780B8 (ru)
BR (1) BRPI0609172A2 (ru)
CA (2) CA2752738C (ru)
EA (2) EA014445B1 (ru)
MX (1) MX2007010272A (ru)
NO (1) NO20074853L (ru)
WO (1) WO2006091646A2 (ru)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759383B2 (en) 2005-02-22 2010-07-20 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
CN101528223B (zh) * 2006-08-30 2013-05-01 密执安州立大学董事会 Mdm2的新型小分子抑制剂和其用途
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
ATE467413T1 (de) * 2006-09-21 2010-05-15 Hoffmann La Roche Oxindolderivate als antikrebsmittel
ATE545416T1 (de) 2006-10-12 2012-03-15 Xenon Pharmaceuticals Inc Verwendung von spiro-oxindol-verbindungen als therapeutika
US7638548B2 (en) * 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
CN101605798A (zh) 2006-12-14 2009-12-16 第一三共株式会社 咪唑并噻唑衍生物
EA200901212A1 (ru) 2007-03-29 2010-04-30 Новартис Аг 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний
WO2008144507A2 (en) * 2007-05-16 2008-11-27 President And Fellows Of Harvard College Spirooxindole inhibitors of aurora kinase
US7834179B2 (en) * 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7776875B2 (en) * 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US7723372B2 (en) * 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
WO2009151069A1 (ja) 2008-06-12 2009-12-17 第一三共株式会社 ４，７－ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
PE20110367A1 (es) 2008-09-18 2011-06-13 Hoffmann La Roche DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CN103664973B (zh) 2008-10-17 2017-04-19 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
US7928233B2 (en) 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8217051B2 (en) 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
NZ599334A (en) 2009-10-14 2014-03-28 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
AU2010319595B2 (en) * 2009-11-12 2015-09-17 The Regents Of The University Of Michigan Spiro-oxindole MDM2 antagonists
US20110118283A1 (en) * 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
US9504671B2 (en) 2010-02-26 2016-11-29 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
CN103153302A (zh) * 2010-04-09 2013-06-12 密歇根大学董事会 针对用于治疗疾病的mdm2抑制剂的生物标记
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
US20120046306A1 (en) * 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
US20120065210A1 (en) * 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
US20120071499A1 (en) * 2010-09-20 2012-03-22 Xin-Jie Chu Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
CA2817585A1 (en) * 2010-11-12 2012-05-18 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
HUE038714T2 (hu) 2011-03-10 2018-11-28 Daiichi Sankyo Co Ltd Dispiropirrolidin származék
CA2835422C (en) * 2011-05-11 2016-10-11 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
CN102627650B (zh) * 2012-03-08 2015-07-08 徐州师范大学 手性四氢吡咯-3,2′-氧化吲哚螺环化合物及其合成方法
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
CN103435622B (zh) * 2013-07-31 2015-11-18 陕西科技大学 一种螺环吲哚二酮哌嗪类生物碱及其合成方法和应用
JP6368311B2 (ja) 2013-09-04 2018-08-01 第一三共株式会社 スピロオキシインドール誘導体の製造方法
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
WO2016001376A1 (en) 2014-07-03 2016-01-07 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
SI3183254T1 (sl) 2014-08-21 2019-08-30 Boehringer Ingelheim International Gmbh Nove spiro(3H-indol-3,2'pirolidin)-2(1H)-onske spojine in derivati kot inhibitorji MDM2-P53
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
ES2968789T3 (es) * 2015-02-20 2024-05-14 Daiichi Sankyo Co Ltd Procedimiento combinado para el tratamiento del cáncer
CN107484415B (zh) * 2015-03-30 2021-01-29 特殊治疗有限公司 作为usp30抑制剂的1-氰基吡咯烷化合物
JP6823587B2 (ja) 2015-04-13 2021-02-03 第一三共株式会社 Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
AR106314A1 (es) 2015-10-09 2018-01-03 Boehringer Ingelheim Int COMPUESTOS DE ESPIRO[3H-INDOL-3,2’-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2 - p53
CN105585570B (zh) * 2015-12-15 2019-10-15 贵州大学 异恶唑拼接吡咯螺环氧化吲哚化合物及其制备方法及应用
SG11201808728QA (en) 2016-04-06 2018-11-29 Univ Michigan Regents Mdm2 protein degraders
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
CA3040840A1 (en) 2016-10-17 2018-04-26 Daiichi Sankyo Company, Limited Combined use of mdm2 inhibitor and dna methyltransferase inhibitor for cancer treatment
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CN107353292B (zh) * 2017-08-23 2018-07-10 山东博苑医药化学有限公司 螺环氧化吲哚乙内酰（硫）脲衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用
CN108486041A (zh) * 2018-03-28 2018-09-04 华南农业大学 PI3K/Akt信号通路在鸡胚成纤维细胞内对马立克氏病毒增殖的应用及其检测方法
CN110680838B (zh) * 2019-11-21 2021-10-01 海门茂发美术图案设计有限公司 一种素心腊梅碱的抗前列腺癌用途
CN112876488B (zh) * 2021-02-18 2021-12-21 苏州大学 螺环吲哚啉衍生物及其制备方法和应用
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN115417871B (zh) * 2022-09-21 2023-06-02 成都理工大学 双螺环吡咯螺氧化吲哚化合物及其合成方法和抗真菌活性
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219661A (en) * 1962-12-14 1965-11-23 Warner Lambert Pharmaceutical Spirooxindole and spirodehydroindole alkaloids and process therefor
GB1056537A (en) * 1963-07-16 1967-01-25 Smith Kline French Lab Improvements in or relating to crystalline alkaloids of mitragyna citiata and compositions thereof
JPH0423184A (ja) * 1990-05-18 1992-01-27 Toshiba Corp 光学的文字読取装置
JP3074281B2 (ja) * 1990-05-30 2000-08-07 住友大阪セメント株式会社 フレキシブルコンテナ
JPH07238069A (ja) * 1994-02-28 1995-09-12 Daicel Chem Ind Ltd 環状アミド化合物の製造方法
RU2084449C1 (ru) * 1994-03-02 1997-07-20 Всероссийский научный центр по безопасности биологически активных веществ 1-бензил-2-оксотриптамин гидрохлорид и его производные, обладающие гепатозащитной активностью
US5773455A (en) * 1996-06-28 1998-06-30 Biomeasure, Incorporated Inhibitors of prenyl transferases
ATE467418T1 (de) * 1997-01-20 2010-05-15 Immodal Pharmaka Gmbh Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung
DK0994890T3 (da) * 1997-06-10 2003-12-01 Univ Michigan Benzimidazolderivater
WO1999012904A1 (en) * 1997-09-08 1999-03-18 Arqule, Inc. Spiro[pyrrolidine-2,3'-oxindole] compounds and methods of use
CN1182083C (zh) * 2001-10-08 2004-12-29 廖宜芳 一种杀虫灭菌的配位肥及其制造方法
CA2468783A1 (en) * 2001-12-18 2003-06-26 F. Hoffmann-La Roche Ag Cis-imidazolines as mdm2 inhibitors

Also Published As

Publication number Publication date
CA2598690C (en) 2011-11-15
EP1856123A4 (en) 2010-12-29
EA201001255A1 (ru) 2011-02-28
CN102627649A (zh) 2012-08-08
AU2006216780B8 (en) 2010-04-22
EP1856123B1 (en) 2016-02-17
WO2006091646A3 (en) 2006-11-30
KR20070108917A (ko) 2007-11-13
JP2008531504A (ja) 2008-08-14
CA2752738A1 (en) 2006-08-31
AU2006216780A1 (en) 2006-08-31
BRPI0609172A2 (pt) 2010-02-23
CN101160314A (zh) 2008-04-09
AU2010202759A1 (en) 2010-07-22
JP2012162550A (ja) 2012-08-30
EA019566B1 (ru) 2014-04-30
CA2598690A1 (en) 2006-08-31
CA2752738C (en) 2014-05-27
JP5248866B2 (ja) 2013-07-31
CN101160314B (zh) 2012-05-23
MX2007010272A (es) 2008-03-12
AU2006216780B2 (en) 2010-04-01
EA014445B1 (ru) 2010-12-30
EP1856123A2 (en) 2007-11-21
AU2010202759B2 (en) 2012-07-19
NO20074853L (no) 2007-11-21
JP5638023B2 (ja) 2014-12-10
WO2006091646A2 (en) 2006-08-31
KR100944301B1 (ko) 2010-02-24
CN102627649B (zh) 2015-03-25

Similar Documents

Publication Publication Date Title
EA200701771A1 (ru) Низкомолекулярные ингибиторы mdm2 и их применение
MX2009002306A (es) Nuevos inhibidores de mdm2 de molecula pequeña y sus usos.
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA200800321A1 (ru) Ингибиторы гистондеацетилазы
EA201070247A1 (ru) Ингибиторы протеасом
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
EA200970156A1 (ru) Пиридизиноновые производные
NO20081636L (no) FAP - inhibitorer
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
EA200700189A1 (ru) Производные хиназолина в качестве ингибиторов parp
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
EA201170772A1 (ru) Органические соединения
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
EA201070278A1 (ru) Ингибиторы гамма-секретазы
EA201100689A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
NO20071127L (no) Triazoloftalaziner
DE602004006433D1 (de) Pyrrol-substituierte indole als inhibitoren von pai-1
EA200601587A1 (ru) Новые амидозамещённые гидрокси-6-фенилфенантридины
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU